| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARHGDIb |
| Uniprot No | P52566 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-201aa |
| 氨基酸序列 | MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LVPRGSHMTE KAPEPHVEED DDDELDSKLN YKPPPQKSLK ELQEMDKDDE SLIKYKKTLL GDGPVVTDPK APNVVVTRLT LVCESAPGPI TMDLTGDLEA LKKETIVLKE GSEYRVKIHF KVNRDIVSGL KYVQHTYRTG VKVDKATFMV GSYGPRPEEY EFLTPVEEAP KGMLARGTYH NKSFFTDDDK QDHLSWEWNL SIKKEWTE |
| 预测分子量 | 49 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ARHGDIb重组蛋白的3篇参考文献示例(注：文献为虚拟示例，实际文献需通过学术数据库检索获取)：
1. **文献名称**：*Expression and Functional Analysis of Recombinant ARHGDIb in Cancer Cell Migration*
**作者**：Li, X. et al.
**摘要**：本研究通过大肠杆菌表达系统成功制备了重组ARHGDIb蛋白，并发现其通过抑制RhoGTP酶(如Rac1和Cdc42)的活性，显著降低乳腺癌细胞的迁移能力，揭示了其在肿瘤转移中的潜在调控作用。
2. **文献名称**：*Structural Insights into ARHGDIb-Rho GTPase Interactions via Crystallography*
**作者**：Wang, Y. et al.
**摘要**：利用重组ARHGDIb蛋白进行X射线晶体学分析，解析了其与RhoA结合的复合物结构，阐明了ARHGDIb通过疏水口袋稳定RhoA非活性状态的分子机制，为靶向设计调控药物提供了结构基础。
3. **文献名称**：*ARHGDIb Recombinant Protein Modulates Neuronal Axon Guidance*
**作者**：Smith, J. et al.
**摘要**：在神经元模型中，外源性重组ARHGDIb蛋白通过干扰Rho信号通路，显著影响生长锥导向，表明其在神经发育和再生中的关键作用。
如需具体文献，建议在PubMed或Web of Science中检索关键词“ARHGDIb recombinant protein”或“RhoGDIβ expression”。
ARHGDIb (Rho GDP-dissociation inhibitor beta), also known as RhoGDI2 or LyGDI, is a member of the RhoGDI family that regulates Rho GTPases, key molecular switches controlling cytoskeletal dynamics, cell migration, and signal transduction. It functions by binding to inactive GDP-bound Rho proteins (e.g., RhoA, Rac1. Cdc42), sequestering them in the cytosol to inhibit premature activation and spatial mislocalization. Structurally, ARHGDIb contains a conserved N-terminal regulatory domain and a C-terminal geranylgeranyl-binding pocket for anchoring prenylated Rho GTPases.
Recombinant ARHGDIb protein is typically produced using bacterial (e.g., E. coli) or mammalian expression systems, enabling studies of its biochemical interactions and therapeutic potential. Its role in cancer metastasis has drawn significant attention, as ARHGDIb is downregulated in advanced tumors and acts as a metastasis suppressor in bladder, gastric, and ovarian cancers. Conversely, it may promote invasiveness in certain contexts, highlighting cell-type-specific functions. In neurodegenerative diseases, ARHGDIb modulates synaptic plasticity through Rho GTPase regulation.
Researchers utilize recombinant ARHGDIb to investigate GTPase cycling mechanisms, screen small-molecule inhibitors, and develop diagnostic biomarkers. Its recombinant form maintains functional integrity for in vitro binding assays, structural studies, and cell-based experiments. Emerging evidence also implicates ARHGDIb in immune regulation, particularly in T-cell activation and macrophage polarization, expanding its relevance to inflammatory diseases. The protein's dual roles in metastasis suppression and pathway activation underscore the complexity of Rho signaling networks in pathophysiology.
×
